You are now leaving the Kedrion website. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.

The Kedrion portfolio of plasma-derived therapies treats a range of disorders and conditions from Albumin for critical care to Anti-D i.m. Immunoglobulin (RhoGAM®) to prevent hemolytic disease in the newborn.  

Our continuing commitment to research, development and innovation, along with our growing industrial capacity and expanding international market presence, contributes to an ever-greater access to effective healthcare for people suffering these debilitating conditions.

Our Therapeutic Areas include: